| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000028880 |
| Receipt No. | R000033047 |
| Scientific Title | A study to investigate the impact of chocolate ingestion on brain function |
| Date of disclosure of the study information | 2017/08/30 |
| Last modified on | 2019/04/22 (Ver. 5) |
| Basic information | ||
| Public title | A study to investigate the impact of chocolate ingestion on brain function | |
| Acronym | A study to investigate the impact of chocolate ingestion on brain function | |
| Scientific Title | A study to investigate the impact of chocolate ingestion on brain function | |
| Scientific Title:Acronym | A study to investigate the impact of chocolate ingestion on brain function | |
| Region |
|
|
| Condition | |||
| Condition | None | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of this study is to assess impact on brain function of intake chocolate |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | MRI brain image |
| Key secondary outcomes | 1)Specialized blood exam
2)Neuropsychological test(Paper based cognitive )tests 3)Subjective evaluation questionnaire |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | chocolate (8 weeks). | |
| Interventions/Control_2 | Placebo chocolate (8 weeks). | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Subjects who competent to consent and give voluntary consent in writing with full understanding after receiving explanation of this study aim and contents.
2) Subjects who are healthy adults of both sexes above 45 years old- under 69 years old and live without receiving any care supports at the point of obtaining informed consent. |
|||
| Key exclusion criteria | 1) Subjects who metallic foreign bodies
2) Subjects who have history of head surgery (including childhood) 3) Subjects who have tattoo, permanent eye shadow, permanent eyebrow, and permanent eyelash extensions 4) Subjects who have history of occupational experience such as metallic abrasive, sheet-metal processing, welding, and lathe working 5) Subjects with claustrophobia 6) Subjects with nyctophobia 7) Subjects whose MMSE score is below 25 8) Subjects who are in pregnancy, lactation, or who are willing to become pregnant during this study 9) Subjects who are under treatment for chronic disorders 10) Subjects who cannot ingest aspartame L-phenylalanine compound (Subjects with phenylketonuria) 11) Subjects who participated in other clinical trial or monitor study within 1 month prior to screening 12) Subject with allergy to cacao, milk constituent and soy 13) Subjects with lactose intolerance 14) Subjects who highly intake cacao products on a daily basis (Cacao-rich chocolate: more than 70g/ week, Milk chocolate: more than 140g/ week) 15) Subjects who highly intake coffee on a daily basis (more than 3 cup of coffee/ day) 16) Subjects who intake medical chemical, quasi-drug, supplement, health food, foods for specified health use, foods with functions claims that potentially influence the outcome of this study, or subjects who plan to intake these during this study (such as health foods or supplement related to brain functions (including ginkgo leave extract, DHA and EPA) or health food containing high polyphenol (Tea of foods for specified health use(such as Iemon-Tokucha or Healthya Green Tea)) within 3 month prior to screening 17) Smokers (including subjects whose non-smoking period is less than 1 year) 18) Subjects who perform exercise more than 3 times a week * Exercise: Training exercise 19) Subjects who is ineligible for this study due to principal investigator's judgment |
|||
| Target sample size | 150 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Meiji Co., Ltd. | ||||||
| Division name | Chocolate & Cacao Technology Development Center Confectionery R&D Laboratories | ||||||
| Zip code | |||||||
| Address | 6-1-2 Fujimi, Tsurugashima-shi, Saitama 350-2201, Japan | ||||||
| TEL | 049-279-1448 | ||||||
| kousuke.ozawa@meiji.com | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | CROee.INC | ||||||
| Division name | Evidence Division | ||||||
| Zip code | |||||||
| Address | 2F YS Build. 1-13-23 Minamiikebukuro Toshima-ku, Tokyo, Japan | ||||||
| TEL | 03-5953-2108 | ||||||
| Homepage URL | |||||||
| imai@croee.com | |||||||
| Sponsor | |
| Institute | CROee.INC |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京センタークリニック(東京都)、東京工業大学(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 132 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033047 |